Clinical Policy: Radiofrequency Ablation of Uterine Fibroids

Description
Uterine leiomyomas are the most common solid pelvic tumors in women and the leading indication for hysterectomy. Many women seek an alternative to hysterectomy because they desire future childbearing or wish to retain their uteri. As alternatives to hysterectomy become increasingly available, it is important to understand the efficacies and risks of these treatments.\(^1\)

This policy describes medical necessity criteria for radiofrequency ablation of uterine fibroids.

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation\(^\circledR\) that there is insufficient evidence in the published peer-reviewed literature to support the safety and effectiveness of radiofrequency ablation and the use of the Acessa™ and Sonata® Systems for the treatment of uterine fibroids.

Background
According to the American College of Obstetricians and Gynecologists (ACOG), uterine fibroids (UF), also called leiomyomas or myomas, are benign growths that develop from the muscle tissue of the uterus. These growths can vary greatly in size, shape, and location. Uterine fibroids are common and estimated to affect 70% of white women and 80% of black women by age 50 years. They are typically detected during a routine pelvic exam.\(^1,2\)

Although many women with UFs are asymptomatic, common symptoms include changes in menstruation, cramping, bleeding at times other than during menstruation, pelvic pressure, pain in the abdomen or lower back, and pain during sex. Women may also experience difficulty or frequent urination or constipation and painful bowel movements. Fibroids can cause an enlarged uterus and abdomen and lead to miscarriages or infertility.\(^1,2\)

Non-surgical treatment for uterine fibroids includes pharmaceutical options such as hormonal contraceptives, nonsteroidal anti-inflammatory drugs, gonadotropin-releasing hormone agonists, progesterone modulators and aromatase inhibitors. Surgical options include myomectomy, the surgical removal of fibroids (which spares the uterus) and hysterectomy, which is the definitive treatment, eliminating the possibility of recurrence. Myomectomy may be performed abdominally, laparoscopically or hysteroscopically depending on the size, number and location of the fibroids.\(^1,2\)

Recently, radiofrequency ablation (RFA) has been introduced as alternative treatment for uterine fibroids. Currently there are two systems for RFA, the Acessa™ system and the Sonata® system.

The Acessa™ Procedure is a minimally invasive, uterine sparing, outpatient treatment for fibroids found within the uterine wall. Using radiofrequency ablation to destroy each fibroid by applying controlled energy through a small needle, the Acessa™ Procedure does not affect surrounding
Radiofrequency ablation of uterine fibroids

...tissues and allows for multiple fibroids to be treated though a single laparoscopic uterine puncture. Additionally, the generator also performs electrocautery to stop bleeding. The body ultimately reabsorbs the destroyed tissue following the procedure.3,4

Regarding the Acessa procedure, Hayes states, in general, a low-quality body of evidence derived from 6 studies (published in 11 articles) suggests that radiofrequency volumetric thermal ablation (RFVTA) may result in improved symptoms and some improvements in general quality of life assessments from baseline. Comparative effectiveness evidence comparing RFVTA with alternative uterine-sparing fibroid treatments is insufficient to draw conclusions. In general, statistically significant differences were not noted in most outcomes; however, comparative analyses were limited to one to two randomized controlled trials and were not always conducted statistically. No studies evaluated success in achieving pregnancy among women attempting to conceive after RFVTA. Three studies limited the eligible patient populations to women who had no desire to maintain fertility. Furthermore, the efficacy of RFVTA for fibroids of varying International Federation of Gynecology and Obstetrics classification was evaluated by only one study. Large, well-controlled trials comparing RFVTA with other minimally invasive, uterine-sparing procedures are needed, especially evaluating the safety and effectiveness of RFVTA among women wishing to maintain fertility.3

The Sonata® System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure to treat symptomatic uterine fibroids. The system also includes a graphical guidance software that provides the operating gynecologist with real-time graphic overlay on the live ultrasound image.5,6

Regarding the Sonata procedure, Hayes states, a very-low-quality body of evidence is insufficient to draw conclusions regarding the efficacy and safety of transcervical RFA for symptomatic UF. Compared with pretreatment status, the Sonata procedure was associated with statistically significant improvements in symptoms, quality of life, and fibroid volume. Due to the limited number of studies, consistency of results cannot be determined. Additional studies comparing the Sonata procedure with established treatments for UF are needed to determine whether the Sonata procedure provides meaningful clinical benefits relative to currently available options. All 3 studies excluded women with an intent for future fertility; however, 2 studies reported that 1 woman in each study conceived, carried to term, and delivered infants.5

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2021, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
CLINICAL POLICY
Radiofrequency ablation of uterine fibroids

<table>
<thead>
<tr>
<th>CPT Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>58674</td>
<td>Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0404T</td>
<td>Trans cervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WellCare’s HS-213 Radiofrequency Ablation of Uterine Fibroids policy adopted. Changed radiofrequency ablation of uterine fibroids to experimental/investigational.</td>
<td>04/20</td>
<td>04/20</td>
</tr>
<tr>
<td>“Experimental/investigational” verbiage replaced in policy statement with descriptive language. References reviewed and updated. All instances of “member” changed to “member/enrollee.”</td>
<td>04/21</td>
<td>04/21</td>
</tr>
</tbody>
</table>

**References**


**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and
接受任何法律责任与内容的任何外部信息所使用或依赖在发展这一临床政策。临床政策与医疗实践标准一致，该临床政策在获准时。该"健康计划"意味着一个健康计划已经采纳了这一临床政策，并且是整个或部分由Centene Management Company, LLC，或其任何附属机构，如果适用的话，进行管理和操作。

目的这一临床政策的目的是提供一个医疗必要性的指南，这是一个组成部分的指导来协助制定覆盖决策和管理福利。它不构成一个合同或保证支付或结果。覆盖决策和福利管理都受所有保险文件（如：证据覆盖，覆盖证书，政策，保险合同等），以及适用的法律和规定的要求和限制。这一临床政策的强制执行由健康计划决定。发布日期可能不等于临床政策的有效日期。如果存在法律或规定要求的差异，法律和规定的要求应予遵守。健康计划保留更改，修改或撤回这一临床政策的权利，以及可能需要时开发和采纳的其他临床政策。

这一临床政策不构成医疗建议，医疗治疗或医疗护理。它不打算指导提供者如何实践医学。提供者应根据医学判断提供最合适的护理，并且独自负责为成员/受保人的医疗建议和治疗。这一临床政策不打算为成员/受保人推荐治疗。成员/受保人应与他们的治疗医生联系以获取诊断和治疗决策。

在这一临床政策中提到的提供者是独立的承包商，他们根据自己的判断行事，并且不受健康计划的控制或权利的控制。提供者不是健康计划的代理人或员工。

这一临床政策是健康计划的财产。未经授权的复制，使用和分发这一临床政策或其中包含的任何信息严格禁止。提供者，成员/受保人和其代表在提供服务或提交付款主张时，应遵守这些条款和条件。如果没有这样的合同存在，提供者，成员/受保人和其代表同意通过提供服务或成员/受保人和/或提交索赔来遵守这些条款和条件。

**注：对于医疗援助成员/受保人**，当州医疗援助覆盖条款与这一临床政策的覆盖条款冲突时，州医疗援助覆盖条款优先。请参阅州医疗援助手册中的任何覆盖条款。
Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.